|apersy| https://validator.w3.org/feed/docs/rss2.html News and insights Home Starting 2025: Don’t forget to look beyond the JCA Exploring access and reimbursement of digital medical devices and AI-based SaMD at ISPOR Europe 2024 November Market Access news recap Not launching in Europe is not the solution. European access preparedness – growing opportunities and risk mitigation Weighing the Costs: Reimbursement of Anti-Obesity Medicines in the US and Europe Nononsense EU JCA The dynamics in diagnostic imaging tenders and funding Uncertainties Surrounding the EU Joint Clinical Assessment: What do biotechs need to monitor Precision medicine and complex care environments. Dynamics in market access and reimbursement. Biotech market access preparedness June market access news recap Apersy’s 1st anniversary What Investors Want You to Know About Regulatory and Market Access Strategies October Market Access news: HTA & pricing policy updates About Apersy France PLFSS 2023: Social security financing bill puts pressure on medicine pricing Microbiome-targeting medicines: Commercial launch is moving centre stage August & September 2022 Market Access news recap July 2022 Market Access news recap Services Apersy at the 11th Microbiome & Probiotic R&D & Business Collaboration Forum: Europe, Rotterdam, 23-24 May 2023 manifest Announcement of UK IDAP Pilot for medical devices – What does it mean for reimbursement? Germany: Changes to innovative drug pricing and AMNOG ahead? 11th Microbiome Forum poster: MAPF French PECAN reimbursement applications have started… It’s not a DiGA copy-paste February 2023 Monthly Reading List March 2023 Monthly Reading List December 2022 Market Access news recap Cookie Policy Legal January 2023 Market Access Reading List Legal Notice & Terms of Use PRIVACY POLICY Contact us